Latest Ratios: P/E Ratio 7.9x · EV/EBITDA 6.0x · ROE N/A. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.5B | $6.4B | $4.8B | $4.1B | $5.0B | $4.5B | $3.7B | $3.6B | $5.0B | $6.0B | $3.8B |
| Enterprise Value | $3.7B | $6.5B | $4.9B | $4.1B | $4.5B | $3.7B | $3.1B | $2.8B | $4.3B | $5.6B | $3.6B |
| P/E Ratio → | 7.87 | 30.30 | 2410.67 | — | — | 22.26 | — | 25.78 | 18.98 | 97.20 | 114.77 |
| P/S Ratio | 2.58 | 5.13 | 4.05 | 3.75 | 5.50 | 5.69 | 5.70 | 4.56 | 5.20 | 5.20 | 3.87 |
| P/B Ratio | — | — | — | — | 96.70 | 22.15 | 44.97 | 17.15 | 75.61 | — | — |
| P/FCF | 114.29 | — | 961.86 | — | — | 14.10 | — | 24.88 | 19.05 | 23.67 | 10.09 |
| P/OCF | — | — | 133.59 | — | — | 12.74 | — | 23.73 | 16.47 | 20.22 | 9.22 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.26 | 4.10 | 3.72 | 4.95 | 4.65 | 4.81 | 3.59 | 4.49 | 4.86 | 3.71 |
| EV / EBITDA | 6.03 | 22.87 | 81.09 | — | — | 15.67 | — | 13.67 | 12.93 | 12.80 | 10.22 |
| EV / EBIT | 13.96 | 22.95 | 88.46 | — | — | 17.04 | — | 13.94 | 14.60 | 28.93 | 26.36 |
| EV / FCF | — | — | 973.06 | — | — | 11.54 | — | 19.56 | 16.44 | 22.16 | 9.67 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.1% | 80.1% | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% | 82.2% | 86.0% | 89.3% | 88.6% |
| Operating Margin | 21.4% | 21.4% | 2.7% | -14.3% | -9.0% | 26.9% | -24.1% | 22.7% | 33.0% | 36.9% | 34.9% |
| Net Profit Margin | 16.9% | 16.9% | 0.2% | -11.8% | -4.9% | 25.9% | -22.9% | 17.1% | 27.4% | 5.3% | 3.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -34.6% | 143.9% | -101.7% | 97.5% | 398.0% | — | — |
| ROA | 16.6% | 16.6% | 0.1% | -7.3% | -2.4% | 12.2% | -9.3% | 8.4% | 17.6% | 4.6% | 4.6% |
| ROIC | 342.7% | 342.7% | — | — | — | — | — | — | — | — | — |
| ROCE | 79.1% | 79.1% | 7.5% | -25.4% | -9.1% | 21.7% | -16.9% | 21.7% | 48.1% | 110.1% | 216.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 5.40 | 1.41 | 3.48 | 1.40 | 3.65 | — | — |
| Debt / EBITDA | 1.23 | 1.23 | 6.25 | — | — | 1.22 | — | 1.42 | 0.72 | 1.10 | 1.52 |
| Net Debt / Equity | — | — | — | — | -9.77 | -4.02 | -6.99 | -3.67 | -10.35 | — | — |
| Net Debt / EBITDA | 0.55 | 0.55 | 0.93 | — | — | -3.47 | — | -3.72 | -2.05 | -0.87 | -0.45 |
| Debt / FCF | — | — | 11.20 | — | — | -2.56 | — | -5.33 | -2.61 | -1.51 | -0.42 |
| Interest Coverage | 6.31 | 6.31 | 1.34 | -3.26 | -2.14 | 8.31 | -6.21 | 9.18 | 9.52 | 3.94 | 2.68 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.71 | 0.71 | 0.89 | 0.98 | 1.24 | 1.80 | 1.98 | 1.83 | 1.62 | 1.43 | 0.96 |
| Quick Ratio | 0.55 | 0.55 | 0.70 | 0.88 | 1.12 | 1.68 | 1.83 | 1.73 | 1.53 | 1.37 | 0.92 |
| Cash Ratio | 0.21 | 0.21 | 0.34 | 0.32 | 0.88 | 1.37 | 1.43 | 1.43 | 1.13 | 1.01 | 0.67 |
| Asset Turnover | — | 1.03 | 0.90 | 0.62 | 0.51 | 0.43 | 0.42 | 0.48 | 0.62 | 0.80 | 0.80 |
| Inventory Turnover | 1.61 | 1.61 | 1.30 | 1.29 | 1.32 | 1.34 | 1.04 | 1.92 | 1.73 | 2.36 | 2.70 |
| Days Sales Outstanding | — | 75.12 | 78.04 | 84.82 | 89.12 | 93.21 | 123.55 | 94.85 | 105.71 | 81.70 | 77.23 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 1.8% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 215.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.7% | 3.3% | 0.0% | — | — | 4.5% | — | 3.9% | 5.3% | 1.0% | 0.9% |
| FCF Yield | 0.9% | — | 0.1% | — | — | 7.1% | — | 4.0% | 5.2% | 4.2% | 9.9% |
| Buyback Yield | 0.3% | 0.2% | 3.6% | 0.8% | 1.8% | 2.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.2% | 3.6% | 0.8% | 1.8% | 2.2% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% |
| Shares Outstanding | — | $128M | $133M | $142M | $139M | $154M | $147M | $151M | $150M | $150M | $149M |
Includes 30+ ratios · 18 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SUPN stock.
Supernus Pharmaceuticals, Inc.'s current P/E ratio is 7.9x. The historical average is 47.9x.
Supernus Pharmaceuticals, Inc.'s current EV/EBITDA is 6.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.2x.
Based on historical data, Supernus Pharmaceuticals, Inc. is trading at a P/E of 7.9x. Compare with industry peers and growth rates for a complete picture.
Supernus Pharmaceuticals, Inc. has 80.1% gross margin and 21.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Supernus Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Negative equity after acquisition
Metrics are mathematically derived from official filings.
Earnings Multiples Diverge Sharply Across Horizons
Based on reported figures, SUPN trades at a trailing P/E of -38.47 but a forward P/E of 9.46, while EV/EBITDA of 26.16 compares with a forward multiple of 2.45, suggesting the market is pricing a sharp earnings recovery that trailing results do not yet show.
The gap between trailing and forward multiples implies analysts expect earnings to normalize materially from the volatile ten-quarter history, where operating margin ranged from -31.4% to 23.2%. Because the forward EV/EBITDA is far below the trailing figure, the valuation depends heavily on whether recent profitability in 2026Q3 proves durable rather than a single strong period. Investors should monitor whether the forward estimates are supported by consistent operating results before relying on the apparent discount.
High Gross Margins Mask Operating Volatility
As reported in the quarterly income statements, SUPN's gross margin held between 84.6% and 90.1% across all ten quarters, yet operating margin swung from 23.2% in 2024Q3 to -31.4% in 2025Q3, indicating that fixed operating spend amplifies revenue variability.
The stability of gross margin points to a high-value product mix with limited cost-driven variance, so the earnings swings appear to originate below the gross profit line. Compared with the sector, the depth of operating losses in several quarters suggests a cost structure that is heavily exposed to revenue timing. Operating margin is therefore a more informative gauge of earning power here than net margin, which is further distorted by non-operating items.
Returns Oscillate Rather Than Compound
Based on SUPN's reported figures, ROIC moved from 3.1% in 2024Q3 to -4.8% in 2025Q3 and back to 26.4% in 2026Q3, a pattern that reflects erratic earnings rather than sustained capital compounding.
The alternation between positive and negative ROIC suggests returns are driven by lumpy quarterly profit rather than a stable improvement in capital efficiency. The 2026Q3 ROE of 28.2% is inflated by the shrinking equity base following negative book equity, so it may overstate true returns. Peers such as HRMY, with ROIC of 42.0%, show that sustained high returns are achievable in this sector, which makes SUPN's inconsistent record a relative weakness.
Debt Build Pressures Negative Equity Position
According to the supplied balance sheet, SUPN's total debt rose from $40.2M to $501.0M in a single quarter, pushing book equity to -$60.0M and lifting leverage to a level where debt-to-equity is no longer meaningful.
The abrupt jump in debt coincides with the large acquisition outflow, which appears to be the principal driver of the leverage shift. Interest coverage is volatile and unreliable across the period, so debt service comfort cannot be assessed with confidence from these quarters alone. Investors should monitor refinancing terms and the timing of repayment, since the negative equity position limits the reliance that can be placed on book-value-based leverage metrics.
Current Ratio Falls as Obligations Rise
Based on reported figures, SUPN's current ratio declined from 2.08 in 2026Q2 to 0.61 in 2026Q3, while cash of $305.0M provides a partial buffer against the increase in current obligations.
The compression below 1.0 indicates that current liabilities now exceed current assets, a shift that warrants further investigation given the acquisition-related debt build. The $305.0M cash position offers meaningful but not complete coverage, and the quick ratio of 0.50 suggests limited liquid cushion beyond cash. Under severe stress, dependence on continued cash generation would be high, given that quarterly free cash flow has alternated between negative and strongly positive.
Forward Multiple Likely Overstates Recovery
The most commonly misapplied metric here is the forward P/E of 9.46, which may flatter SUPN because it relies on normalized earnings from a business whose quarterly results have alternated between profit and sizable losses.
Forward P/E is typically applied to businesses with predictable earnings, but SUPN's ten-quarter record shows operating margin swinging across more than fifty percentage points, so the forward figure rests on an assumption of stability the history does not support. A more reliable alternative is to normalize earnings across a full cycle or to value the company on cash generation averaged over several periods, rather than on a single forward estimate.